Data updated: Jun 28, 2026
Growth Hormone Deficiency Clinical Trial Landscape
Growth Hormone Deficiency is being studied across 97 clinical trials registered since 2008, with 15 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 7 active Phase 2 trials, and 2 active Phase 1 trials.
Top industry sponsors include Changchun GeneScience Pharmaceutical Co., Ltd., Lumos Pharma, Xiamen Amoytop Biotech Co., Ltd..
Trial activity
15 active / 97 total since 2008
Active by phase 5 Ph3 / 35 7 Ph2 / 30 2 Ph1 / 19 1 Ph4 / 13
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Changchun GeneScience Pharmaceutical Co., Ltd. 4 6 1
Lumos Pharma 4 2 0
Xiamen Amoytop Biotech Co., Ltd. 1 1 0
Kexing Biopharm Co., Ltd. 1 0 0
Novo Nordisk 0 15 0
OPKO Health, Inc. 0 6 1
Versartis Inc. 0 3 4
Pfizer 0 3 2
Ascendis Pharma Endocrinology Division A/S 0 4 0
Teva Branded Pharmaceutical Products R&D, Inc. 0 2 2
Ascendis Pharma A/S 0 3 0
EMD Serono 0 2 1
How the field has grown
New-trial starts peaked in 2016 (7 registered); 2025 saw 7. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (21 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 7
2017 7
2018 2
2019 4
2020 2
2021 5
2022 1
2023 4
2024 3
2025 7
2026 5
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (3) 162
2017 (5) 62
2018 (1) 434
2019 (2) 144
2020 (1) 264
2021 (4) 139
2022 (0) 0
2023 (0) 0
2024 (0) 0
2025 (2) 220
2026 (3) 150
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06948214 RECRUITING
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma n=150
NCT07553351 RECRUITING
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
Kexing Biopharm Co., Ltd. n=192
NCT04867317 RECRUITING
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
VA Office of Research and Development n=172
NCT07126288 NOT YET RECRUITING
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
Shenzhen Kexing Pharmaceutical Co., Ltd. n=268
NCT07129759 NOT YET RECRUITING
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma n=150
NCT05171855 COMPLETED
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=220
NCT03811535 COMPLETED
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Novo Nordisk A/S n=200
NCT04970654 COMPLETED
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Novo Nordisk A/S n=110
NCT02968004 COMPLETED
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
OPKO Health, Inc. n=224
NCT04615273 COMPLETED
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=264
NCT04786873 COMPLETED
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
AEterna Zentaris n=101
NCT03344458 COMPLETED
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Ascendis Pharma A/S n=298
NCT04633057 COMPLETED
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
TJ Biopharma Co., Ltd. n=168
NCT04513171 COMPLETED
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
Xiamen Amoytop Biotech Co., Ltd. n=434
NCT03223025 COMPLETED
Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency
Cinnagen n=30
NCT01909479 TERMINATED
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
OPKO Health, Inc. n=202
NCT02413138 TERMINATED
Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
Versartis Inc. n=41
NCT02410343 TERMINATED
Study of TV-1106 in Growth Hormone-Deficient Adults
Teva Branded Pharmaceutical Products R&D, Inc. n=14
NCT02781727 COMPLETED
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Ascendis Pharma Endocrinology Division A/S n=162
NCT03305016 COMPLETED
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S n=146
NCT02410356 TERMINATED
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
Teva Branded Pharmaceutical Products R&D, Inc. n=34
NCT03831880 COMPLETED
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
Pfizer n=87
NCT03874013 COMPLETED
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
OPKO Health, Inc. n=44
NCT02229851 COMPLETED
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
Novo Nordisk A/S n=301
NCT03075644 COMPLETED
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Novo Nordisk A/S n=62
NCT02382939 COMPLETED
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Novo Nordisk A/S n=92
NCT02558829 COMPLETED
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
AEterna Zentaris n=157
NCT03145831 TERMINATED
A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency
Versartis Inc. n=21
NCT02173821 COMPLETED
A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency
Ferring Pharmaceuticals n=23
NCT01237340 TERMINATED
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
EMD Serono n=59
NCT00630487 TERMINATED
Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency
Pfizer n=9
NCT00884000 COMPLETED
A Study of Zomacton in Children With Growth Hormone Deficiency
Ferring Pharmaceuticals n=165
NCT01112865 COMPLETED
Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
Pfizer n=120
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only